Cargando…
Development and Validation of Nine Deprescribing Algorithms for Patients on Hemodialysis to Decrease Polypharmacy
BACKGROUND: Polypharmacy is ubiquitous in patients on hemodialysis (HD), and increases risk of adverse events, medication interactions, nonadherence, and mortality. Appropriately applied deprescribing can potentially minimize polypharmacy risks. Existing guidelines are unsuitable for nephrology clin...
Autores principales: | Lefebvre, Melissa J., Ng, Patrick C. K., Desjarlais, Arlene, McCann, Dennis, Waldvogel, Blair, Tonelli, Marcello, Garg, Amit X., Wilson, Jo-Anne, Beaulieu, Monica, Marin, Judith, Orsulak, Cali, Lloyd, Anita, McIntyre, Caitlin, Feldberg, Jordanne, Bohm, Clara, Battistella, Marisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7605037/ https://www.ncbi.nlm.nih.gov/pubmed/33194213 http://dx.doi.org/10.1177/2054358120968674 |
Ejemplares similares
-
Development and Validation of Patient Education Tools for
Deprescribing in Patients on Hemodialysis
por: Cho, Thomas Hyunwoo, et al.
Publicado: (2023) -
Polypharmacy and deprescribing: challenging the old and embracing the new
por: O’Donnell, Lisa Kouladjian, et al.
Publicado: (2022) -
Deprescribing in Real Time: Hospitalized Septuagenarian With Polypharmacy
por: Famuyiro, Tolulope, et al.
Publicado: (2023) -
Correction to: Polypharmacy and deprescribing: Challenging the old and embracing the new
por: O’Donnell, Lisa Kouladjian, et al.
Publicado: (2022) -
Deprescribing Opportunities for Hospitalized Patients With End-Stage
Kidney Disease on Hemodialysis: A Secondary Analysis of the MedSafer Cluster
Randomized Controlled Trial
por: Moryousef, Joseph, et al.
Publicado: (2022)